Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation

Atsushi Nakajima,*† Sonoko Ishizaki,† Kazuki Matsuda,† Shinsuke Kurosu,† Shinya Taniguchi,† Per-Göran Gillberg,‡ Jan P Mattsson,¶ Tomoko Hasunuma§ and Michael Camilleri¶ ¶

*Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, †EA Pharma Co., Ltd., §Kitasato University Kitasato Institute Hospital, Tokyo, Japan; ¶Albireo AB, Gothenburg, Sweden; ‡Mayo Clinic, Rochester, Minnesota, USA

Key words
bile acids and salts, constipation, elobixibat, gastrointestinal agents, lithocholic acid.

Accepted for publication 12 January 2022.

Correspondence
Dr Atsushi Nakajima, Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Email: nakajima-tky@umin.ac.jp

Clinical trial registration: Japan Registry of Clinical Trials, jRCTs031180035 (https://jct.niph.go.jp/en-latest-detail/JRCTs031180035).

Declaration of conflict of interest: AN served as advisors to EA Pharma Co., Ltd. SK, KM, and ST are employees of EA Pharma Co., Ltd. PG and JM are employees of Albireo AB and own stock/stock options in Albireo Pharma, Inc. TH has no conflict of interest to declare. AN and MC conceived and designed the study. TH acquired the data; KM and SK interpreted the data. AN and MC drafted the manuscript. All authors reviewed the manuscript drafts for important intellectual content and approved the final version of the manuscript for submission.

Abstract

Background and Aim: Elobixibat is a locally acting inhibitor of the ileal bile acid transporter. We compared bile acid metabolism between healthy subjects and patients with chronic constipation and assessed changes in the bile acid profile after elobixibat administration in the latter group.

Methods: Healthy subjects (n = 10) and patients with chronic constipation (n = 19) were assessed as inpatients for 7 days, during which they received meals containing ~60 g/day of fat. Patients with chronic constipation remained as inpatients for a further 7 days for once-daily elobixibat administration. Assessments included concentrations of fecal and serum bile acids, serum 7α-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19, and bowel movements and constipation symptoms.

Results: Fecal total and primary bile acids were significantly lower in patients with chronic constipation versus healthy subjects. Serum C4 and fibroblast growth factor 19 levels were comparable between groups. Elobixibat treatment increased fecal total and primary bile acids and decreased levels of fecal lithocholic acid and serum total as well as secondary bile acids in patients with chronic constipation. Bowel movements and other constipation-related symptoms were also improved by elobixibat to levels almost comparable with those of healthy subjects.

Conclusions: Despite comparable C4 levels, patients with chronic constipation demonstrated decreased levels of fecal bile acids versus healthy subjects. Elobixibat treatment increased fecal bile acid excretion and reduced serum bile acid concentrations. The improvement of constipation after elobixibat treatment was associated with increased total bile acids, particularly primary bile acids.

Financial support: The study and writing/editing assistance were funded by EA Pharma Co., Ltd.

Introduction

Bile acids (BAs) are physiological laxatives that stimulate colonic secretion1 and motility.2 Elobixibat (formerly A3309), a novel, locally acting inhibitor of the ileal BA transporter (IBAT),3 prevents enterohepatic circulation of BAs, leading to colonic BA accumulation. It was approved in Japan for the treatment of chronic constipation in January 2018.

After being released into the duodenum, most BAs are actively reabsorbed via the IBAT and transported to the liver. Approximately 15% of conjugated BAs escape this process and enter the colon, where primary BAs (cholic acid [CA] and chenodeoxycholic acid [CDCA]) undergo deconjugation and dehydroxylation into secondary BAs (including deoxycholic acid [DCA] and lithocholic acid [LCA]). Additionally, ursodeoxycholic acid is produced by gut microbiota.4,5 Deconjugated BAs are passively reabsorbed through the colonic mucosa; consequently, approximately 5% of BAs are fecally excreted.

Constipation is associated with reduced fecal or serum BAs in children6 and adults.7 A study of patients with

Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation

Atsushi Nakajima,*† Sonoko Ishizaki,† Kazuki Matsuda,† Shinsuke Kurosu,† Shinya Taniguchi,† Per-Göran Gillberg,‡ Jan P Mattsson,¶ Tomoko Hasunuma§ and Michael Camilleri¶ ¶

*Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, †EA Pharma Co., Ltd., §Kitasato University Kitasato Institute Hospital, Tokyo, Japan; ¶Albireo AB, Gothenburg, Sweden; ‡Mayo Clinic, Rochester, Minnesota, USA

Key words
bile acids and salts, constipation, elobixibat, gastrointestinal agents, lithocholic acid.

Accepted for publication 12 January 2022.

Correspondence
Dr Atsushi Nakajima, Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Email: nakajima-tky@umin.ac.jp

Clinical trial registration: Japan Registry of Clinical Trials, jRCTs031180035 (https://jct.niph.go.jp/en-latest-detail/JRCTs031180035).

Declaration of conflict of interest: AN served as advisors to EA Pharma Co., Ltd. SK, KM, and ST are employees of EA Pharma Co., Ltd. PG and JM are employees of Albireo AB and own stock/stock options in Albireo Pharma, Inc. TH has no conflict of interest to declare. AN and MC conceived and designed the study. TH acquired the data; KM and SK interpreted the data. AN and MC drafted the manuscript. All authors reviewed the manuscript drafts for important intellectual content and approved the final version of the manuscript for submission.

Abstract

Background and Aim: Elobixibat is a locally acting inhibitor of the ileal bile acid transporter. We compared bile acid metabolism between healthy subjects and patients with chronic constipation and assessed changes in the bile acid profile after elobixibat administration in the latter group.

Methods: Healthy subjects (n = 10) and patients with chronic constipation (n = 19) were assessed as inpatients for 7 days, during which they received meals containing ~60 g/day of fat. Patients with chronic constipation remained as inpatients for a further 7 days for once-daily elobixibat administration. Assessments included concentrations of fecal and serum bile acids, serum 7α-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19, and bowel movements and constipation symptoms.

Results: Fecal total and primary bile acids were significantly lower in patients with chronic constipation versus healthy subjects. Serum C4 and fibroblast growth factor 19 levels were comparable between groups. Elobixibat treatment increased fecal total and primary bile acids and decreased levels of fecal lithocholic acid and serum total as well as secondary bile acids in patients with chronic constipation. Bowel movements and other constipation-related symptoms were also improved by elobixibat to levels almost comparable with those of healthy subjects.

Conclusions: Despite comparable C4 levels, patients with chronic constipation demonstrated decreased levels of fecal bile acids versus healthy subjects. Elobixibat treatment increased fecal bile acid excretion and reduced serum bile acid concentrations. The improvement of constipation after elobixibat treatment was associated with increased total bile acids, particularly primary bile acids.

Financial support: The study and writing/editing assistance were funded by EA Pharma Co., Ltd.

Introduction

Bile acids (BAs) are physiological laxatives that stimulate colonic secretion1 and motility.2 Elobixibat (formerly A3309), a novel, locally acting inhibitor of the ileal BA transporter (IBAT),3 prevents enterohepatic circulation of BAs, leading to colonic BA accumulation. It was approved in Japan for the treatment of chronic constipation in January 2018.

After being released into the duodenum, most BAs are actively reabsorbed via the IBAT and transported to the liver. Approximately 15% of conjugated BAs escape this process and enter the colon, where primary BAs (cholic acid [CA] and chenodeoxycholic acid [CDCA]) undergo deconjugation and dehydroxylation into secondary BAs (including deoxycholic acid [DCA] and lithocholic acid [LCA]). Additionally, ursodeoxycholic acid is produced by gut microbiota.4,5 Deconjugated BAs are passively reabsorbed through the colonic mucosa; consequently, approximately 5% of BAs are fecally excreted.

Constipation is associated with reduced fecal or serum BAs in children6 and adults.7 A study of patients with
constipation-predominant irritable bowel syndrome (IBS) found that although ~15% displayed BA deficiencies compared with healthy controls, only 4.4% exhibited decreased fasting serum 7α-hydroxy-4-cholesten-3-one (C4, a precursor of BAs and surro
gate marker for de novo BA synthesis). Bile acids are signaling molecules involved in lipid metabo-
lism, electrolyte transport or colonic motility, and immune responses. BAs can also modulate microbial balance in the gut, which alters the pool of BAs. Considering this metabolic crosstalk between intestinal BAs and microbiota, characterization of BA profile modulation after elobixibat administration is war-
ranted. Previous evaluation of BA composition in stools in re-
sponse to elobixibat treatment was conducted in outpatients.11 Given the day-to-day intrasubject variability and heterogeneity in the BA composition of a single stool, there are concerns about the validity of fecal sampling methods, particularly collection du-
ration and control of dietary fat and fiber intake. Notably, the results of a qualitative and quantitative study concluded that stool samples should be collected for at least 3 days, and ideally 5 days, to avoid errors. The role of BAs has been investigated in constipation-predominant IBS, but not in other forms of chronic constipation; therefore, investigating the associations between types of constipation is important for understanding the clinical importance of elobixibat.

We conducted a study in participants admitted to a clinical re-
search center that included provision of standard meals and a 6-day stool collection timescale. We compared serum and fecal BA metabolism between healthy subjects and patients with chronic constipation after elobixibat administration to investigate the change in BA profiles and to explore the accuracy of different stool sampling methods.

Materials and methods

Study design. This was an open-label, single-center study conducted between October 31, 2018 and October 30, 2019. Participants were recruited nationwide from the applicant pool for clinical research and were enrolled in the order their applications were received; remuneration for participation was provided.

After screening, all participants entered a run-in period, followed by a 1-week hospitalization (baseline period). After Day 7, healthy subjects left the center, while patients with chronic constipation remained for a further 7 days to receive elobixibat treatment. Oral elobixibat (10 mg) was administered 30 min before breakfast once daily; the dose could be up-/down-titrated as necessary (Fig. 1).

Participants underwent 10.5 h of fasting before admission. The center provided meals containing ~60 g of fat (~1550 kcal/day); meals were identical for both groups and for both the baseline and treatment weeks. Appropriate nutrition was determined ac-
cording to the results of a Japanese health and nutrition survey, and participants were instructed to finish the provided food. Other food or drink (particularly alcohol and caffeine) was not permitted, with the exception of water or caffeine-free, roasted barley tea.

The clinical research review board of the Kitasato Institute ap-
poved the study protocol (approval no. CRB3180002). This study was performed in accordance with the ethical standards laid down by the Declaration of Helsinki (as revised in Brazil 2013) and was registered on the Japan Registry of Clinical Trials (jRCT) website (Identifier: jRCTs031180035). Written informed consent was ob-
tained from each study participant.

Participant selection. All participants were Japanese, aged ≥ 20 years, with no clinically significant medical history (e.g. liver dysfunction) and were not taking medications, supple-
ments, or probiotics that could interfere with the study assessments or compromise participant safety.

Healthy subjects were defined as individuals who defecated al-
most every day for ≥ 6 months; subjects with ≤ 3 spontaneous bowel movements (SBMs) per week within 1 week of the run-in period were excluded.

Patients with chronic constipation were defined as those who satisfied the Rome IV criteria for functional constipation and had a mean Bristol stool form scale (BSFS) score of ≥ 3 during Week 2 of the run-in period. Exclusion criteria conformed with those of a previous study11 and additionally included rescue medication use within 72 h after defecation and/or four times during the 2-week admission period or during the 1-week baseline.

Sample collection and analytical methods. Blood samples were collected before elobixibat administration on Days 1, 7, and (in patients with chronic constipation only) 14 for mea-
surement of fasting C4, fibroblast growth factor 19 (FGF19; which downregulates BA synthesis), and BAs. A second sample for mea-
surement of serum BAs was collected at 2, 4, 8, and 12 h after breakfast.

Fecal sampling was performed as collections every 48 h for 6 days during the baseline (Days 2–3, 4–5, and 6–7) and treatment (Days 9–10, 11–12, and 13–14) periods, with fecal weight measured im-
mediately after each defecation. A stool sample was collected (~3 g) from the middle part of the feces and stored at −20°C for a single-stool measurement. The remaining stool was homogenized, and one-tenth of the total fecal weight was stored at −20°C. These 48-h fecal samples were subsequently thawed, mixed, and homog-
ized for measurement of BAs and stool liquidity.

Methods of BA extraction, analysis, and validation are de-
scribed in Data S1. Serum BAs and biomarkers were measured at LSI Medience Corporation (Tokyo, Japan). Serum total BA was measured by enzymatic colorimetric assay and a BioMajesty™ instrument (series JCA-BM8060; JEOL Ltd., To-
kyo, Japan). Serum concentration of FGF19 was measured using the Quantikine® enzyme-linked immunosorbent assay kit (R&D Systems, Inc., Minneapolis, MN, USA). Fecal BAs were quanti-
fied at the Techno Suruga Laboratory (Shizuoka, Japan). For stool liquidi

Outcomes. The primary outcome was the change in total fecal BAs from baseline to the end of elobixibat treatment in patients with chronic constipation. Secondary outcomes included between-group differences in fecal and serum concentrations of to-
tal and individual BAs, and in serum C4 and FGF19 (both markers.
for BA absorption/malabsorption); changes in pharmacodynamic parameters after elobixibat administration in patients with chronic constipation; between-group differences in pharmacodynamic parameters; and effects of treatment on bowel characteristics. A post-hoc analysis explored the correlation of fecal total BA concentration between 3 g of single-stool samples collected over 6 days and a 6-day stool sample.

Bowel characteristics included fecal weight, stool liquidity, and stool consistency score assessed by the BSFS (averaged over the elobixibat treatment week), numbers of SBMs/week and complete SBMs (CSBMs)/week. Other constipation-related symptoms included straining, abdominal bloating, abdominal discomfort, and constipation severity; each was assessed using a 5-point subjective scale (none, mild, moderate, severe, and very severe).

Safety was assessed using adverse event (AE) monitoring and clinical laboratory tests; AEs were classified using the Medical Dictionary for Regulatory Activities version 21.1.

**Statistical analyses.** Baseline data between groups were compared with a Wilcoxon rank sum test. Baseline and post-treatment data from patients with chronic constipation...
were compared using a Wilcoxon signed-rank test. A linear-trapezoidal method was employed to estimate the area under the effect curve (AUEC) for serum BAs. Total serum BAs were defined by the enzymatic assay value, whereas total fecal BAs were defined as the sum of individual BAs obtained by mass spectrometry. Fecal primary BAs were defined as CA + CDCA, and fecal secondary BAs as DCA + LCA. C4 and FGF19 concentrations falling below the lower limit of quantification (LLOQ) were imputed by half LLOQ concentration. Serum and fecal BA values falling below the LLOQ were imputed as zero. When a subject did not defecate within the 48-h collection period, the value was zero. Correlation of fecal BA concentrations between 3 g of single-stool samples collected over 6 days and 6-day stool samples was conducted using Lin’s concordance correlation coefficient.

Statistical data were analyzed using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA) by IDD, Inc. (Tokyo, Japan).

Results

Participants. Overall, 10 healthy subjects and 20 patients with chronic constipation met the inclusion criteria, provided consent, and were admitted to the study center (Fig. 1). One patient with chronic constipation withdrew during the baseline period, resulting in 10 healthy subjects and 19 patients with chronic constipation. Of the 19 patients receiving elobixibat, 9 were down-titrated to 5 mg/day and 10 maintained a 10-mg dose. There were no protocol deviations.

Most participants were female (healthy subjects, 9/10 [90.0%]; patients with chronic constipation, 17/20 [89.5%]). Baseline demographics were generally comparable between the healthy subject and patient groups (mean ± standard deviation [SD] age: 42.8 ± 15.3 and 43.4 ± 12.4 years, respectively; body mass index: 20.5 ± 1.4 and 22.9 ± 3.0 kg/m², respectively). Table 1 shows baseline characteristics at baseline.

Fecal and serum bile acid characteristics at baseline. Patients with chronic constipation had significantly lower mean total fecal weight, stool liquidity, total fecal BAs, and primary BAs/gram of dry stool versus healthy subjects (Table 2). DCA concentrations were slightly lower and LCA 1.5-fold higher in patients versus healthy subjects.

The mean ± SD AUECs from 0 to 12.5 h (AUEC₀–₁₂.₅ h) of total serum BAs at baseline in healthy subjects and patients with chronic constipation were 58.2 ± 21.2 and 80.1 ± 42.4 μmol·h/L, respectively. The mean ± SD changes in serum C4 and FGF19 concentrations from Days 1 to 7 were comparable between healthy subjects and patients with chronic constipation (C4: 24.2 ± 23.6 and 25.7 ± 16.3 ng/mL, respectively; FGF19: 199.3 ± 74.5 and 202.0 ± 74.5 ng/mL, respectively). Table 2 shows fecal characteristics of participants at baseline.

Table 1  Bowel function at baseline and effect of elobixibat treatment

| Mean ± SD       | Healthy subjects (n = 10) | Patients with chronic constipation (n = 19) | P value† |
|-----------------|--------------------------|--------------------------------------------|---------|
|                 | Baseline period          | Elobixibat treatment period                |         |
| SBMs per week   | 10.9 ± 6.0               | 2.0 ± 0.7                                  | 12.7 ± 2.8*** |
| CSBMs per week  | 9.3 ± 6.6                | 0.5 ± 0.5                                  | 6.4 ± 4.0*** |
| Stool consistency score | 3.8 ± 1.0               | 2.1 ± 0.9                                  | 4.6 ± 1.1*** |

Data from the 7-day baseline period are shown for healthy subjects, and data from the 7-day baseline period and the 7-day elobixibat treatment period are shown for patients with chronic constipation.

†P < 0.001 versus patients with chronic constipation at baseline.

Table 2  Fecal characteristics of participants at baseline

| Mean ± SD       | Healthy subjects (n = 10) | Patients with chronic constipation (n = 19) | P value† |
|-----------------|--------------------------|--------------------------------------------|---------|
| Total wet fecal weight (g/day) | 124.7 ± 52.9              | 34.0 ± 24.8                                | <0.0001 |
| Total dry fecal weight (g/day) | 23.2 ± 4.7                | 9.5 ± 6.2                                  | <0.0001 |
| Stool liquidity (%) | 79.8 ± 4.7                | 69.5 ± 5.8                                  | <0.0001 |
| Fecal total BAs (μmol/day) | 688.2 ± 645.4            | 202.0 ± 208.3                              | 0.0017 |
| Total BAs per gram of wet stool (μmol/g) | 5.1 ± 3.1              | 5.5 ± 3.0                                  | 0.5726 |
| Total BAs per gram of dry stool (μmol/g) | 27.6 ± 20.8            | 18.5 ± 10.0                                | 0.4026 |
| CA (μmol/g) | 7.8 ± 13.8                | 0.9 ± 1.7                                  | 0.0306 |
| CDCA (μmol/g) | 5.0 ± 8.5                | 0.8 ± 1.1                                  | 0.0321 |
| DCA (μmol/g) | 9.1 ± 6.6                | 8.8 ± 5.8                                  | 0.9461 |
| LCA (μmol/g) | 4.6 ± 3.6                | 7.0 ± 3.9                                  | 0.1378 |
| UDCA (μmol/g) | 0.9 ± 1.2                | 0.5 ± 1.0                                  | 0.2249 |

Data from the 7-day baseline period are shown for healthy subjects and for patients with chronic constipation.

†Compared with healthy subjects at baseline.

BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; SD, standard deviation; UDCA, ursodeoxycholic acid.
185.7 ± 103.9 pg/mL, respectively), indicating that no patients had BA synthesis deficiency.

**Effect of elobixibat on bile acids in patients with chronic constipation.** Following elobixibat treatment, total fecal weight, total fecal BAs, and stool liquidity all increased significantly compared with baseline (Table 3). The total fecal BA excretion in elobixibat-treated patients was 2.1-fold higher than in healthy subjects. However, total dry fecal weights were comparable between groups.

In elobixibat-treated patients, significant changes in the primary BA concentration (25.4-fold increase from baseline), LCA concentration (3.9-fold decrease from baseline), and ursodeoxycholic acid concentration (3.8-fold increase from baseline) were observed; the DCA concentration remained almost unchanged (Table 3).

Following treatment, fasting serum C4 levels increased by 223%, and FGF19 levels decreased by 35%, indicating increased BA synthesis (Table 4). The AUEC0–12.5 h of total serum BAs decreased (Table 4 and Fig. 2), while that of secondary BAs significantly decreased (Table 4 and Fig. S1). The AUEC0–12.5 h of total serum BAs was slightly higher in elobixibat-treated patients versus healthy subjects.

There were no differences in total quantity of fecal BAs, total serum BAs, C4, or FGF19 concentrations in patients in whom elobixibat was down-titrated to 5 mg/day compared with those continuing to receive 10 mg/day.

| Mean ± SD | Patients with chronic constipation (n = 19) | P value† |
|----------|------------------------------------------|---------|
| Baseline period | Elobixibat treatment period | |
| Total wet fecal weight (g/day) | 34.0 ± 24.8 | 187.6 ± 91.9 | < 0.0001 |
| Total dry fecal weight (g/day) | 9.5 ± 6.2 | 23.5 ± 8.1 | < 0.0001 |
| Stool liquidity (%) | 69.5 ± 5.8 | 95.3 ± 6.4 | < 0.0001 |
| Fecal total BAs (μmol/day) | 202.0 ± 208.3 | 1436.3 ± 808.5 | < 0.0001 |
| Total BAs per gram of wet stool (μmol/g) | 5.5 ± 3.0 | 7.7 ± 1.8 | < 0.01 |
| Total BAs per gram of dry stool (μmol/g) | 18.5 ± 10.0 | 58.2 ± 22.3 | < 0.0001 |
| CA (μmol/g) | 0.9 ± 1.7 | 25.9 ± 14.7 | < 0.0001 |
| CDCA (μmol/g) | 0.8 ± 1.1 | 17.3 ± 9.9 | < 0.0001 |
| DCA (μmol/g) | 8.8 ± 5.8 | 8.9 ± 7.3 | 0.5412 |
| LCA (μmol/g) | 7.0 ± 3.9 | 1.8 ± 3.5 | 0.0002 |
| UDCA (μmol/g) | 0.5 ± 1.0 | 1.9 ± 2.7 | 0.0003 |

Data from the 7-day elobixibat treatment period are shown for patients with chronic constipation.

† Compared with patients with chronic constipation at baseline.

BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; SD, standard deviation; UDCA, ursodeoxycholic acid.

| Mean ± SD | Patients with chronic constipation (n = 19) | P value† |
|----------|------------------------------------------|---------|
| Baseline period | Elobixibat treatment period | |
| Fasting C4 (ng/mL) | 25.7 ± 16.3 | 83.1 ± 64.8 | < 0.0001 |
| Fasting FGF19 (pg/mL) | 185.7 ± 103.9 | 119.9 ± 63.6 | 0.0124 |
| Fasting total BAs (μmol/L) | 3.8 ± 2.1 | 3.1 ± 2.0 | 0.1134 |
| Total BAs AUEC0–12.5 h (μmol/L*h) | 80.1 ± 42.4 | 62.2 ± 22.8 | 0.0323 |
| CA group (μmol/L*h) | 7.3 ± 8.0 | 9.2 ± 11.3 | 0.8288 |
| CDCA group (μmol/L*h) | 36.2 ± 25.1 | 41.9 ± 17.2 | 0.0663 |
| DCA group (μmol/L*h) | 26.3 ± 22.0 | 5.2 ± 7.1 | 0.0002 |
| LCA group (μmol/L*h) | 0.8 ± 0.7 | 0.1 ± 0.2 | < 0.0001 |
| UDCA group (μmol/L*h) | 9.6 ± 10.4 | 5.8 ± 5.4 | 0.0160 |

Data from day 14 (elobixibat treatment period) are shown for patients with chronic constipation. Individual BA groups indicate the total of tauroconjugated and glycoconjugated and unconjugated BAs.

† Compared with patients with chronic constipation at baseline.

AUEC0–12.5 h, area under the effect curve from 0 to 12.5 h; BA, bile acid; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; SD, standard deviation; UDCA, ursodeoxycholic acid.
**Correlation between stool samples.** The correlation of total fecal BA concentration between 3 g of single-stool samples collected over 6 days and 6-day stool samples was assessed using a wet fecal weight. One patient with chronic constipation who defecated only once in 6 days had a total fecal weight of 9 g; therefore, 1 g was collected for the 6-day stool sample. There were no other patients whose 6-day single-stool sample was < 3 g. Correlation coefficients for healthy subjects, patients with chronic constipation at baseline, and elobixibat-treated patients were 0.8887, 0.8278, and 0.5979, respectively (Fig. 3).

**Effects on bowel functions.** Following elobixibat administration, SBMs and CSBMs in patients with chronic constipation were almost comparable with healthy subjects (Table 1). The BSFS stool consistency score also improved after treatment, from 2.1 (hard and lumpy) to 4.6 (soft and smooth). Additionally, subjective constipation-related symptoms improved with elobixibat (Fig. S2).

**Safety.** No subject experienced AEs or serious AEs leading to study discontinuation. In total, 8/10 (80%) healthy subjects experienced AEs, of which diarrhea (4/10 [40%]) and hard stool (4/10 [40%]) were the most frequent (Table 5). No AEs occurred in patients with chronic constipation during the baseline period; during the treatment period, 18/19 (94.7%) patients experienced AEs, of which abdominal pain (15/19 [78.9%]) and diarrhea (7/19 [36.8%]) were most frequently reported.

**Discussion**

This study confirmed that patients with chronic constipation have reduced excretion of feces and total fecal BAs, and decreased SBMs, compared with healthy subjects. After 1 week of elobixibat treatment, BA levels and constipation symptoms improved to levels comparable with healthy subjects. Both groups had similar changes in fasting serum C4 and FGF19 during the baseline period, indicating that no patients with chronic constipation had reduced BA synthesis at baseline according to the previously reported lower limit of normal (C4 < 5.05 ng/mL).8 The excreted total BAs per gram of wet stool were comparable between groups,
although the excreted total BAs per gram of dry stool were lower in patients with chronic constipation.

Notably, the AUEC0–12.5 h, of total serum BAs (particularly secondary BAs) was higher in patients with chronic constipation versus healthy subjects. Given that patients had decreased fecal BA excretion and lower SBMs despite their normal BA synthesis rates, the increase in total serum and secondary BAs is likely due to stool retention, resulting in passive BA reabsorption further down the colon. Stool retention also provides more time and opportunity for the colonic dehydroxylation of CDCA to LCA and may cause the increased concentration of fecal LCA in patients with chronic constipation. These data are consistent with a previous study that reported that fecal LCA could be a predictor for primary BAs (CA + CDCA) was considerably higher (74.1%) after versus before treatment (9.1%), consistent with a previous study that administered an IBAT inhibitor to healthy subjects.19 Conversely, a recent prospective study reported a smaller (1.5-fold) increase in fecal BAs after 2 weeks of treatment with elobixibat in patients with chronic constipation.20 The reasons for this discrepancy may include the study design (random sampling of fecal samples and no control of dietary nutrition), patient demographics (older age vs our study), and frequency of bowel movements during treatment (low vs our study).20

In serum BA concentrations assessed with AUEC0–12.5 h, primary BAs were increased; this was attributed to increased hepatic BA synthesis and high levels of primary BAs in the colon, resulting in increased passive colonic absorption. Serum secondary BA levels were considerably lower in elobixibat-treated patients than in healthy subjects. Thus, primary and secondary BA levels in the colon following elobixibat treatment were comparable, and SBM frequency increased, leading to shorter colonic retention time and a reduction in BA biotransformation by colonic microbiota.

Abdominal pain and diarrhea were the most frequent AEs, consistent with the results of a large-scale, long-term phase 3 trial conducted in Japan.11 High AE frequency was also observed in the previous phase 1 trial;21 however, AE frequency decreased during long-term elobixibat administration. Notably, the healthy subjects in this analysis also experienced fecal-related AEs (diarrhea and hard stools). The hospitalization period required for the study baseline may have caused stress for healthy individuals, impacting bowel function. High fecal total BAs per gram of wet stool have previously been associated with diarrhea in patients with IBS; however, fecal total BAs per gram of wet stool in elobixibat-treated patients were 1.5-fold higher than in healthy subjects. Increased fecal BAs are associated with increased wet fecal weight, and stool liquidity is most likely caused by the increase in both BA synthesis and excretion after elobixibat administration.

The evaluation of sample collection procedures found that concentrations of total BAs per gram of wet stool had moderate correlations during the baseline period in both groups. However, the correlation coefficient in patients with chronic constipation during the treatment period was low, indicating that the BA and water content in a single stool of elobixibat-treated patients were heterogeneous.

Limitations of this study include the small sample size and lack of a placebo or active control group. Although the impact of elobixibat treatment on colonic transit has been previously established,23,24 whether microbial composition in the intestine is altered following elobixibat treatment warrants further investigation. Another limitation was the 1-week study duration, which meant we could not determine the long-term impact of elobixibat administration on BAs, though long-term efficacy of elobixibat has been confirmed; we speculate that BA levels in stools would increase, although further investigation is needed to confirm this.

In conclusion, this inpatient study was able to minimize factors such as food intake that affect BA synthesis rates. Improvement of constipation after elobixibat treatment is associated with increased total BAs and, in particular, primary BAs (Fig. S3). Further long-term studies with larger sample sizes are needed to clarify microbial compositions associated with increased BA synthesis after elobixibat administration.

### Table 5

| AEs, n (%) | Healthy subjects† | Patients with chronic constipation† |
|-----------|-------------------|-------------------------------------|
| Any AE    | 8 (80.0)          | 18 (94.7)                           |
| AE leading to discontinuation | 0                  | 0                                   |
| Abdominal pain | 1 (10.0)        | 15 (78.9)                           |
| Diarrhea  | 4 (40.0)          | 7 (36.8)                            |
| Hard stool | 4 (40.0)          | 0                                   |
| Abdominal distension | 0          | 2 (10.5)                            |
| Nausea    | 0                 | 2 (10.5)                            |
| Upper abdominal pain | 0          | 2 (10.5)                            |
| Increased blood triglycerides | 2 (20.0)      | 0                                   |
| Back pain | 0                 | 1 (5.3)                             |
| Chills    | 0                 | 1 (5.3)                             |
| Erythema  | 0                 | 1 (5.3)                             |
| Headache  | 0                 | 1 (5.3)                             |
| Increased alanine aminotransferase | 0          | 1 (5.3)                             |
| Increased transaminase | 0          | 1 (5.3)                             |
| Thirst    | 0                 | 1 (5.3)                             |
| Eyelid swelling | 1 (10.0)    | 0                                   |

†During the baseline period.

‡During the elobixibat administration period (no AEs were observed in this group during the baseline period).

AE, adverse event.

Elobixibat effects on bile acids
Elobixibat effects on bile acids

A Nakajima et al.

Acknowledgments

The authors would like to thank the study participants for their contributions and the staff at Kitasato University Kitasato Institute Hospital for their support with data acquisition. We thank Tadao Kunihiro, PhD (Techno Suruga Laboratory Co., Ltd.), for assessing fecal bile acids and Makio Tokiwa (IDD, Inc.) for conducting the statistical analysis. We also thank Mie Yamamoto, PhD (SunFlare Co., Ltd.), who wrote the first draft of the manuscript based on input from the authors, and Sally-Anne Mitchell, PhD, Edanz, Japan, for editorial assistance.

References

1 Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J. Clin. Invest. 1971; 50: 1569–77.
2 Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook IJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G443–9.
3 Gillberg PG, Dahlström M, Starke I, Östlund-Lindqvist AM. The IBAT inhibition by A3309—a potential mechanism for the treatment of constipation. Gastroenterology 2010; 138 S-224 (abstract S1301).
4 Di Ciula A, Garruti G, Lunardi Baccetto R et al. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J. Pediatr. Gastroenterol. Nutr. 2008; 47: 596–606.
5 Hofmann AF. Increased deoxycholic acid absorption and gall stones in arogeomalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 2005; 54: 575–8.
6 Vijayvargiya P, Busciglio I, Burton D, Donato L, Lucke A, Camilleri M. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin. Gastroenterol. Hepatol. 2018; 16: 522–7.
7 Hofmann AF. Increased deoxycholic acid absorption and gall stones in arogeomalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 2005; 54: 575–8.
8 Vijayvargiya P, Busciglio I, Burton D, Donato L, Lucke A, Camilleri M. Bile acid deficiency in a subgroup of patients with irritable bowel syndrome with constipation based on biomarkers in serum and fecal samples. Clin. Gastroenterol. Hepatol. 2018; 16: 522–7.
9 Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016; 7: 22–39.
10 Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 2018; 15: 111–28.
11 Nakajima A, Seki M, Taniguchi S et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol. Hepatol. 2018; 3: 537–47.
12 Cummings JH, Wiggins HS, Jenkins DJ et al. Influence of diets high and low in animal fat on bowel habit, gastrointestinal transit time, fecal microflora, bile acid, and fat excretion. J. Clin. Invest. 1978; 61: 953–63.
13 Marlett JA, Hosig KB, Vollendorf NW, Shinnick FL, Haack VS, Story JA. Mechanism of serum cholesterol reduction by oat bran. Hepatology 1994; 20: 1450–7.
14 Sanel KD, Ives JA, Cashmore GC, Lawson AM. On the homogeneity of stools with respect to bile acid composition and normal day-to-day variations: a detailed qualitative and quantitative study using capillary column gas chromatography-mass spectrometry. Clin. Chim. Acta 1987; 162: 257–75.
15 Ministry of Health, Labour and Welfare. The National Health and Nutrition Survey in Japan, 2016. Available at: https://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h28-houkoku.pdf (accessed July 2021).
16 Lyutakov I, Ursini F, Penchev P et al. Methods for diagnosing bile acid malabsorption: a systematic review. BMC Gastroenterol. 2019; 19: 185.
17 Vijayvargiya P, Camilleri M, Burton D, Busciglio I, Lucke A, Donato L. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2019; 49: 744–58.
18 Chadwick VS, Gaginella TS, Carlson GL, Deboning JC, Phillips SF, Hofmann AF. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J. Lab. Clin. Med. 1979; 94: 661–74.
19 Graffner H, Gillberg PG, Rikner L, Marschall HU. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. Aliment. Pharmacol. Ther. 2016; 43: 303–10.
20 Misawa N, Higurashi T, Takatsu T et al. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. Aliment. Pharmacol. Ther. 2020; 52: 821–8.
21 Kumagai Y, Amano H, Sasaki Y et al. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomized controlled trial. Br. J. Clin. Pharmacol. 2018; 84: 2393–404.
22 Dior M, Delagreverie H, Duboc H et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol. Motil. 2016; 28: 1330–40.
23 Simren M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation—a double-blind study. Aliment. Pharmacol. Ther. 2011; 34: 41–50.
24 Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zimmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am. J. Gastroenterol. 2011; 106: 2154–64.